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Abstract 
Purpose: To investigate the anti-proliferative activity of free and nanoencapsulated gedunin against 
human non-small-cell lung cancer (NCI-H292) cells.  
Methods: Gedunin-loaded nanoliposomes (LG) were prepared using thin-film hydration method. Anti-
proliferative effects of free and LD were evaluated by sulforhodamine B (SRB) assay. Apoptotic effects 
of gedunin-loaded liposomes were assessed by evaluating expressions of p53, Bax and survivin genes, 
caspase 3/7 activities, DNA fragmentation and morphological changes after staining with Hoechst 
33342 and acridine orange/ethidium bromide (AO/EB). 
Results: Cell proliferation data and microscopic visualization demonstrated a higher anti-proliferative 
activity for LG than the encapsulant (liposomes) alone. LG exhibited dose- and time-dependent 10-fold 
anti-proliferative activity compared to the free drug, while displaying tolerable belligerence towards 
normal human lung fibroblast (MRC-5) cells. Apoptosis detection assays and gene expression analysis 
revealed the transcriptional modulation of the apoptosis-related genes (p53, survivin and Bax), 
increased activity of caspase 3/7 and the condensation of nuclear chromatin, implying the induction of 
apoptosis by the nano-formulation in NCI-H292 cells.  
Conclusion: LG may therefore be considered as a potential nano-formulation which can target non-
small-cell lung cancer. 
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Lung cancer ranks as the most common cancer 
among men worldwide and every year 
approximately 1.35 million lung cancer cases are 
diagnosed. It ranks as the major cause of cancer 
deaths among Asian males [1]. Of the two major 
types (small-cell and non-small-cell) of lung 
cancer, non-small-cell lung cancer (NSCLC) is 
the most common type [2]. Though 
chemotheraphy, radiotheraphy and surgeries are 
the only available treatment options for lung 
cancer pateints, chemo and radiotheraphy cause 
severe side effects. Thus, finding an effective 
Nwokwu et al 
Trop J Pharm Res, September 2017; 16(9): 2080  
 
chemotherapeutic solution with fewer side effects 
will improve the prognosis of NSCLC patients. 
 
Plant-derived anti-cancer compounds play a 
major role in the field of anti-cancer drug 
discovery and some natural compounds have 
been approved for clinical use [3]. Although 
many anti-cancer drugs have been isolated from 
natural sources, several challenges such as 
short half-lives, high metabolic instability, low 
solubility leading to poor absorption and systemic 
bioavailability are mainly associated with the 
development of anti-cancer drugs into a globally 
acceptable level. Further, drug resistance, rapid 
degradation of the drug, large dosage 
requirement, and undesirable toxicity are also 
existing challenges [4]. Research on nano-
pharmaceuticals has helped overcome these 
challenges and a number of nano-material-based 
therapeutic approaches have been used for 
cancer treatment while some are under clinical 
development [5]. Lipid-based nano-particles 
(liposomes) have gained much attention as they 
possess some unique properties such as 
conjugation with targeting moieties like 
antibodies, ease of degradation under specific 
conditions, and drug-cargo-carrying capacity [6].  
 
Gedunin is one of the major compounds present 
in the neem tree and it is an Hsp90 inhibitor [7]. 
Anti-proliferative effects of gedunin have also 
been reported in several cancer cells such as 
colon, prostate, ovarian, pancreatic, breast and 
cervical. However, anti-proliferative effects of 
gedunin in lung cancer have not been evaluated 
so far [7,8]. Since gedunin is poorly soluble (due 
to hydrophobic nature)  in the aqueous 
extracellular environment which limits its 
bioavailability and pharmacokinetic profile, we 
hypothesize that nano-formulations of gedunin 
may enhance its anti-proliferative and apoptotic 
effects in lung cancer cells.Therefore, this study 
was planned to evaluate anti-proliferative and 
apoptotic effects of gedunin-loaded liposomal 
nano-particles in human non-small-cell lung 






Cell culture medium and reagents were 
purchased from the American Type Culture 
Collection (ATCC), Rockville, MD, USA. 
Caspase-Glo 3 and 7 assay kit was a product of 
Promega. Egg yolk phosphatidylcholine (approx. 
60 %, TLC) and cholesterol (≥ 99.0 %), dialysis 
tubing (12 000 MWCO), ethanol, methanol and 
acetonitrile (HPLC grade) were purchased from 
Sigma-Aldrich.  Gedunin was procured from 
Santa Cruz Biotechnology, Texas (sc-203967). 
Deionized water was filtered through a 0.45 μm 
cellulose nitrate filters (Sartorius Stedim Biotech 
GmbH 37070, Goettingen, Germany). All other 
chemicals and reagents used in this study were 
of analytical grade and purchased from Sigma 
Aldrich Chemical (St. Louis, MO, USA) unless 




NCI-H292 (non-samll cell lung cancer) and MRC-
5 (normal human lung Fibroblast) cell lines were 
purchased from American Type Culture 
Collection (ATCC), Rockville, MD, USA. Cell 
lines were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM), supplemented with 10 
% fetal bovine serum (FBS), and a 0.1 % 
antibiotic cocktail (penicillin/streptomycin). Cells 
were seeded in T–25 flasks, incubated in a 
humidified atmosphere of 5 % CO2 at 37 oC to 70 
– 80 % confluence and sub-cultured as a mono-
layer. 
 
Preparation of liposomal nano-formulation 
 
LG were prepared using the thin-film hydration 
method originally described [9]. 
Phosphatidylcholine (100 mg), cholesterol (20 
mg) and gedunin (1 mg) in 5 mL ethanol were 
dissolved in 25 mL chloroform.  Then, a thin film 
of lipids was prepared after evaporating the 
organic solvents using a rotary evaporator. The 
lipid film was allowed to dry overnight at room 
temperature in a vacuum oven and hydrated with 
10 mL phosphate buffered saline (PBS, pH 7.4) 
with continuous stirring to incorporate the 
gedunin. The liposomal suspension was kept 
overnight at 4 – 8 °C, to complete hydration. 
Then, the liposomal suspension was sonicated 
for 5 min at 4 °C in a sonicating bath. It was then 
dialyzed against PBS (pH 7.4) for 3 days at 4 °C 
to purify LG. the Liposome nano-particles were 
sterilized by autoclaving at 121 oC for ~ 15 min, 
followed by slow cooling for ~ 1 h [10].  
 
Characterization of LG 
 
LG (500 μL) was dissolved in 10 mL ethanol and 
the solution was analyzed by HPLC in a reversed 
phase C18 column. Deionized water and 
acetonitrile were used for gradient elution in 
which the percentage of acetonitrile was 
increased from 30 to 100 % gradually over a 
period of 20 min. Next, 100 % acetonitrile was 
eluted for 5 min. The flow rate used throughout 
the analysis was 1 mL/min. The wavelength used 
for the detection of gedunin was 224 nm and the 
retention time was 13.7 min. A series of 
concentrations of ethanol gedunin solutions was 
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used for the construction of the standard curve. 
These data were used for calculating 
encapsulation efficiency (EE) and loading 
capacity (LC). Particle sizes of liposomes were 
determined using dynamic light scattering 
technique (zetasizer NanoZS, Malvern 
Instruments, UK) fitted with a red laser of 633 
nm. Liposome suspensions were diluted in PBS 
and the samples were equilibrated at 25 °C. 
Then, scattering intensity was measured at an 
angle of 173˚ relative to the incident radiation. 
Particle size was obtained from size distribution 
by intensity. Zeta-potential of the same liposomal 
suspensions described above were measured 
using Laser Doppler Electrophoresis technique. 
The values reported are the mean zeta-potential 




NCI-H292 and MRC-5 (5 x 103 cells per well) 
cells were seeded in 96-well tissue culture plates 
(BD Biosciences, Cowley, UK). The cells were 
then incubated for 24 h temperature before 
treatment with test compounds. After incubation, 
six serially diluted gedunin concentrations (1.56 – 
50 µg/mL) and media containing LG (at six serial 
concentrations ranging from 0.50 to 15 µg/mL) 
were tested for anti-proliferative activity by 
sulphorhodamine B (SRB) assay [11]. Three time 
intervals (24, 48 and 72 h) were used and the 
standard anticancer drug paclitaxel (at the same 
doses with LG) was used as the positive control. 
Prior to the SRB assay, wells were washed with 
PBS (three times) and fixed in ice-cold 50 % 
trichloroacetic acid (TCA) at 4 oC for 1 h. The 
cells were then stained with 0.4 % SRB dye 
(prepared in 1 % acetic acid) for 15 min at room 
temperature and washed off with 1 % acetic acid, 
and subsequently solubilized with 10 mM Tris-
base in a plate shaker for 1 h at room 
temperature. Absorbance was measured at a 
wavelength of 540 nm using a microplate reader 
(Synergy HT, USA). Half-maximal inhibitory 





Microscopic images of untreated and treated 
cells were captured using an inverted phase-
contrast microscope (Olympus CKX41, Japan) to 





Cells cultured on (2 x 104 cells/well) coverslips in 
24-well tissue culture plate, were treated with 
liposomal gedunin (1, 2 and 4 µg/mL) for 24 h. 
Following incubation, the wells were washed with 
PBS and fixed with 4 % formaldehyde (pH 7.4) at 
room temperature for 15 min. The cells were 
washed again with 1 mL PBS and triple-stained 
in the dark with three dyes: acridine 
orange/ethidium bromide and Bis-benzimide 
(Hoechst 33258) and observed under a 
fluorescence microscope (Olympus, BX51TRF, 
Japan). 
 
Caspase 3/7 activity assay 
 
Caspase3/7 activity in liposomal gedunin treated 
NCI-H292 cells was measured using Caspase-
Glo 3/7 assay kit (Promega) according to 
manufacturer’s protocol. 
 
DNA fragmentation analysis 
 
NCI-H292 cells (1 x 106 cells) were treated with 
LG at 1, 2 and 4 µg/mL and paclitaxel (4 µg/mL) 
for 48 h. Cells were collected by trypsinization 
and centrifugation. Resulting pellets were 
washed with ice-cold PBS to remove cell debris 
present. Freshly prepared lysis buffer (5 mL), 
containing Tris-HCl (5 mM, pH 8.0), EDTA (5 
mM, pH 8.0), 0.5% SDS, 1 M NaCl, proteinase K 
(0.1 mg/mL), RNase (0.03 mg/mL) and 
autoclaved distilled water was added to each 
sample (300 μL) and incubated for 1 h in a 55 °C 
water-bath. DNA was extracted by phase 
separation method [11]. The DNA pellet was then 
re-dissolved in 20 μL autoclaved distilled water 
and equal amount of DNA (1 µg) was loaded 
onto the 2% agarose gel containing ethidium 
bromide (0.5 µg/mL) and run along with 100 bp 
ladder at 55 V for 3 h. The banding pattern was 
visualized by UV illumination using a Gel-Doc 
system (Quantum-ST4 1100/20M). 
 
Real-time quantitative PCR of apoptosis-
related genes 
 
The NCI-H292 cells were sub-cultured (2 x 105 
cells/mL) in T-25 tissue culture flasks and 
maintained for 24 h. They were treated with 
liposomal gedunin (0.5 and 1 µg/mL) and 
incubated for another 24 h along with an 
untreated control. TRIzol reagent was used to 
extract RNA.  Extracted RNA (2 µg) was mixed 
with 50 ng of random primers and 13.5 µL of 
ultrapure PCR water to make a total volume of 
25 µL and incubated for 5 min at 70oC. cDNA 
was then synthesized by adding 5 µL 10 mM 
dNTP mix,  5 µL  MMLV 5X reaction buffer,  25 
units of RNasin and MMLV RT enzyme (200 
units), and the reaction mixture (25 µL) was 
incubated at 37 oC for 60 min in a thermal cycler. 
Stratagene Mx3000P real-time PCR system 
(Agilent Technologies, CA, USA) was used to 
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perform quantitative real-time PCR (qPCR) with 
the help of MESA Green qPCR MasterMix Plus 
for SYBR® Assay (Eurogentec, Seraing, Liège, 
Belgium) with primers previously described [12]. 
The reaction mixture (25 µL) contained 0.5 µL of 
respective forward and reverses primers, 12.5 µL 
SYBR Green MasterMix and water. GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) 
was used as the internal control. The thermal 
cycle programme was as follows: denaturation at 
95 oC for 10 min, 40 cycles of denaturation at 95 
oC for 30 s, annealing at 56 oC for 1 min, and 
extension at 72 oC for 30 s. The relative 
quantification of each gene expression profile 




All data in this study are expressed as 
mean±standard deviation of three independent 
experiments. GraphPad Prism 6.0.1 software 
(GraphPad Software Inc., San Diego, CA, USA) 
was used for statistical analysis and two-way 
analysis of variance (ANOVA) with Tukey’s 
multiple comparisons test was used to determine 
significant differences between experimental 
groups. The differences were considered 




Characteristics of liposomal gedunin 
formulation 
 
The prepared nanoparticles showed 
polydispersity index of 0.709 and exhibited 
characteristics of successful encapsulation, as 
determined by HPLC. Encapsulation efficiency 
(EE), loading capacity (LC), particle size 
distribution and zeta-potential of nanoparticles 




The IC50values of the free gedunin, liposomal 
gedunin, and the standard anticancer drug, 
paclitaxel for NCI-H292 and MRC-5 cells, as well 
as their safety factors, are displayed in Table 2. 
Free gedunin showed significant (p < 0.05) dose-
dependent and a time-dependent cytotoxic effect 
in NCI-H292 cells and it was less cytotoxic to 
MRC-5 cells. Liposomal gedunin also exerted 
significant (p < 0.05) dose-dependent and time-
dependent cytotoxic effects in NCI-H292 cell. 
However, liposomal gedunin showed higher 
cytotoxic effects in NCI-H292 cells than to pure 
gedunin and paclitaxel. Paclitaxel demonstrated 
higher cytotoxicity in MRC-5 cells than to 
prepared liposomal gedunin nano-particles. 
 
Cytomorphological changes  
 
Phase-contrast microscopic images obtained in 
the presence and absence of treatments, as 
shown in Figure 1, depict dose-dependent as 
well as time-dependent characteristic 
cytomorphological changes: cell shrinkage, 
cytoplasmic granulation, surface blebbing and 
blistering and cell lysis were the major visible 
hallmarks of apoptosis. 
 
Caspases 3 and 7 activities  
 
According to the results obtained, all three doses 
(0.0125, 0.0625 and 1 µg/mL) of liposomal 
gedunin increased the activity of caspase 3 and 
7 in a dose-dependent manner, which was only 
significant (p = 0.03) for the highest dose (Fig 2). 
 










86.82 7.2  10-3 394.1 ± 89.4 -54.1 ± 5.91 
 
Table 2: IC50 (µg/mL) and safety factors for the test compounds and the standard anticancer drug, Paclitaxel on 
cancerous and normal lung cell lines at different experimental timelines 
 
Formulation NCI-H292 MRC-5 
 24 h 48 h 72 h 24 h 48 h 72 h 
Gedunin 26.430 24.640 21.600 >50 >50 >50 












*Bold data in brackets represent the safety factor, i.e. evaluation of the biotoxicity of test compounds on 
cancerous (NCI-H292) cells relative to normal (MRC-5) cells, determined as the ratio of IC50 value for MRC-5 
cells to that for NCI-H292 cells – the higher the value, the safer the drug. An IC50 value for liposome (without 
drug) was not detected within the highest dose tested (100 ppm) 
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Figure 1: Cytomorphological changes in [A] NCI-H292 and [B] MRC-5 cells following 24, 48 and 72 h  drug 
treatments, as observed under a phase-contrast light microscope: Across rows: Untreated control; G = Gedunin 




Figure 2: Dose-dependent activation of effector caspases 3 and 7 in untreated and liposomal gedunin--treated 
NCI-H292 cells. Error bars indicate the ± standard deviation of three replicates. p = 0.03*; p value represents the 
significance of the difference between the control and the treated groups (two-way ANOVA). P < 0.05 indicates 
significant difference among treatments 
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DNA fragmentation  
 
Typical DNA fragmentation was not observed in 
liposomal gedunin and paclitaxel treated cells. 
However, a small smearing of DNA was 
observed at 3 and 4 µg/mL treatments compared 




Figure 3: Electropherogram showing induction of 
high-molecular-weight DNA fragmentation in response 
to drug exposure: 1 – Untreated control; 2, 3, 4 – 
Liposomal gedunin (1, 2, and 4 µg/mL); 5 – Paclitaxel 
(4 µg/mL); 6 – 100bp DNA ladder. 
 
Gene expressions of p53, Bax and Survivin 
 
The data presented in Figure 4 indicate that 
liposomal gedunin significantly up-regulated the 
expression of the genes p53 and Bax (p < 
0.0001). However, a slight down regulation of the 
expression of the anti-apoptotic gene, survivin 
was observed in liposomal gedunin treated cells. 
 
Morphological changes observed under 
fluorescence microscope 
 
Morphological changes of the cells treated with 
liposomal gedunin were observed with the help 
of a fluorescence microscope after staining with 
Hoechst 33342 and acridine orange/ethidium 
bromide (AO/EB) (Figure 5). Viable control cells 
containing normal nuclei reflected bright green 
fluorescence, while apoptotic cells that have lost 
their membrane integrity exhibited different 
chromophorous (orange to red staining) 
characteristics (cells stained with AO/EB). 
Granulations in the nucleus were observed in 
cells treated with liposomal gedunin, whereas no 





In this study, we have demonstrated the 
enhanced in vitro anti-cancer activity of improved 
gedunin by liposomal nano-encapsulation in non-
small-cell lung cancer (NCI-H292) cell line. When 
considering anti-proliferative effects of liposomal 
gedunin and free gedunin, liposomal gedunin 
showed greater anti-proliferative effects in NCI-
H292 cells than to free gedunin. Moreover, 
liposomal gedunin is less cytotoxic to normal 
lung fibroblast cells (MRC-5) than the positive 
control (paclitaxel). Drugs with IC50 values as low 
as 4 or 10 µM have been identified as highly 
potent cytotoxic agents [14-16]. Thus liposome-
encapsulated gedunin fits into this class of 
anticancer drug leads and may therefore, be 
considered a potent formulation. Furthermore, 
liposomal gedunin with comparatively less 
cytotoxicity to the MRC-5 cells than the positive 
control, paclitaxel, highlights the possible use of 
liposomal gedunin as a more potent drug lead for 
the treatment of lung cancer. 
 
Figure 4: Liposomal gedunin-induced changes in expression of apoptosis-related genes (p53 and Bax; **p < 
0.0001); Survivin (*p > 0.05)] after basal normalization with a reference gene (GAPDH); an arbitrary figure of one 
(1) was allotted to all control samples as a calibrator; p < 0.05 indicates significant difference among treatments 
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Figure 5: Apoptotic changes in NCI-H292 cells following 24 h drug treatments, as observed under a fluorescence 
microscope: A = Control 1 (AO/EB); B = Control 2 (H); C = Gedunin (12.5 µg/mL, AO/EB); D = Gedunin (12.5 
µg/mL, H); E = Gedunin (25 µg/mL, AO/EB); F = Gedunin (25 µg/mL, H); G = Liposomal gedunin (1 µg/mL, 
AO/EB); H = Liposome (1 µg/mL, H); I = Liposomal gedunin (4 µg/mL, AO/EB); J = Liposomal gedunin (4 µg/mL, 
H) (Note: AO/EB- stained with acridine orange/ethidium bromide and H-stained with Hoechst 33342) 
 
Apoptosis is important in homeostasis of organs 
and tissues. Deregulation of apoptosis is one of 
the hallmark features of cancer [17]. Apoptosis 
involves activation of proteases, known as 
caspases (via extrinsic or intrinsic pathway), 
shrinkage of cells, fragmentation of DNA,  
chromatin condensation and formation of 
apoptotic bodies, etc. Genes Bax and p53 play 
an important role in apoptosis. Bax and p53 are 
highly expressed in apoptotic cells [17]. 
Moreover, p53, regulates the anti-apoptotic gene, 
survivin.  
 
In the present study, apoptosis detection assays 
and apoptotic related gene expression analysis 
indicate induction of apoptosis in liposomal 
gedunin treated NCI-H292 cells. The 
fluorescence microscopic images after 24 h 
treatment further indicated that liposomal 
gedunin caused death of NCI-H292 cells mainly 
by apoptosis. The significant increase of Bax and 
caspase 3 and 7 activity in liposomal gedunin 
treated cells suggest the involvement of the 
intrinsic mitochondrial pathway of apoptosis. It 
has been reported that Bax induces the release 
of complex proteins such as cytochrome C, and 
calcium ions (Ca2+), from the mitochondria into 
the cytosol, activating the intrinsic pathway of 
p53-mediated apoptosis [18,19]. Significant up-
regulation (33-fold) of p53 could be linked to an 
alternative pathway of apoptosis induction or 
other DNA damage pathways [20]. 
 
Induction   of   apoptosis   was   not   sufficiently  
reflected by DNA fragmentation pattern obtained 
in the present study. Certain cells have also been 
reported to undergo apoptosis without 
degradation of the nuclear DNA implicitly due to 
the activities of inhibitor of caspase-activated 
DNase [21]. DNA fragmentation is a hallmark of 
late apoptosis which is highly dependent on the 
inducing agent, endonuclease class and tissue-
specificity [21].  
 
The physico-chemical characteristics of 
nanoparticles hold crucial implications for their 
capacity as drug delivery vehicles, their fate and 
toxicity [5-6]. As shown in Table 1 the 
encapsulation efficiency of liposomes (86.82%) 
was as high as those produced by other 
researchers [22] , but the ones used in the 
present study were of larger size distribution (394 
nm), and had an anionic zeta potential (-54) in 
contrast to their cationic liposomes. Unlike 
anionic liposomes, cationic liposomes cause 
induction of  cellular stress  and change in gene 
expression [22]. Most of the phosphatidylcholines 
usually used for liposomal drug delivery have 
been proven as non-toxic [5,6]. Particle size is 
instrumental to enhanced permeation and 
retention (EPR) effect, cellular internalization, 
sub-cellular trafficking, degradation and 
clearance. A size range of ≤ 100 nm is rapidly 
and efficiently internalized [23]. Although 
liposomal nano particles prepared in the present 
study were not in the standard nanoparticle size 
range, other researchers have been reported an 
effective  chitosan nanoparticles  within a size  
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range of  150 – 350 nm which is almost similar to 
the size of the nano particles used in the present 
study  [24,25]. This observation underscores the 
need for implementing metrology standards 
related to nanoparticle suspensions in order to 
ensure uniformity and reproducibility. 
Collectively, the enhanced cytotoxicity of the 
liposomal formulation is a function of successful 
gedunin encapsulation and intensified uptake 
into the cells after treatment, thus validating the 
quality of the nano-formulation and the 





Enhanced anti-cancer activity of an improved 
gedunin is achieved by liposomal 
nanoencapsulation. This is the first documented 
evidence to demonstrate that nano-encapsulated 
(liposomal) gedunin enhances anti-proliferative 
effects against human non-small-cell lung cancer 
(NCI-H292) cells through p53-initiated, Bax-
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